What is Part B: Multiple-dose ATM-AVI, Cohorts 1-4 used for?

Part B: Multiple-dose ATM-AVI, Cohorts 1-4 is indicated for Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older, Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options, Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy, Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings, Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings.

Who makes Part B: Multiple-dose ATM-AVI, Cohorts 1-4?

Part B: Multiple-dose ATM-AVI, Cohorts 1-4 is developed by Pfizer.

What development phase is Part B: Multiple-dose ATM-AVI, Cohorts 1-4 in?

Part B: Multiple-dose ATM-AVI, Cohorts 1-4 is FDA-approved (marketed).

What is the generic name of Part B: Multiple-dose ATM-AVI, Cohorts 1-4?

part-b-multiple-dose-atm-avi-cohorts-1-4 is the generic (nonproprietary) name of Part B: Multiple-dose ATM-AVI, Cohorts 1-4.

Last reviewed 2026-04-20 · How we verify

Part B: Multiple-dose ATM-AVI, Cohorts 1-4 (part-b-multiple-dose-atm-avi-cohorts-1-4)

Pfizer · FDA-approved active Quality 37/100

The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified.

Part B: Multiple-dose ATM-AVI, developed by Pfizer, holds a significant market position with 50 approved indications, making it a leading therapeutic option in its class. Its competitive advantage lies in the ability to be administered alongside systemic IV antivirals, unlike Meropenem and other carbapenem-type antibiotics which cannot be used concurrently. A key risk is the requirement for a PD-L1 companion diagnostic for several indications, which may limit its broader application and increase treatment complexity. Despite having no ongoing clinical trials, the extensive list of approved indications suggests a robust and well-established pipeline.

At a glance

Generic name	part-b-multiple-dose-atm-avi-cohorts-1-4
Sponsor	Pfizer
Drug class	Antiretroviral
Target	HIV-1
Therapeutic area	Infectious Disease
Phase	FDA-approved

Mechanism of action

Unfortunately, the provided information does not include a detailed explanation of the drug's mechanism. However, it is a treatment for HIV-1 infection, which suggests that it targets the virus or the immune system's response to it.

Approved indications

Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings

Common side effects

No common side effects on file.

Drug interactions

Atazanavir
Atazanavir
Atazanavir
Atazanavir
Atazanavir
Atazanavir
Atazanavir
Atazanavir
Atazanavir
Atazanavir
Atazanavir
Atazanavir

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Part B: Multiple-dose ATM-AVI, Cohorts 1-4 CI brief — competitive landscape report
Part B: Multiple-dose ATM-AVI, Cohorts 1-4 updates RSS · CI watch RSS
Pfizer portfolio CI